Advertisement

DNA repair gene polymorphisms in non-small-cell lung cancer patients treated with first-line platinum-containing chemotherapy

Abstract

Purpose

Single nucleotide polymorphisms (SNPs) in the DNA repair genes are believed to contribute to the clinical outcome of patients receiving platinum-based chemotherapy. We investigated the impact of 2 SNPs of excision repair cross-complementation group 1 and 2 of xeroderma pigmentosum complementation group G on the outcome in patients with non-small-cell lung cancer (NSCLC) treated with platinum-based chemotherapy.

Methods

Between October 2007 and March 2012, we collected 374 blood samples from consecutive patients registered in the TAILOR trial. Four SNPs (rs11615, rs3212986, rs17655, rs1047768) were genotyped using real-time polymerase chain reaction.

Results

The rs11615 polymorphism was associated with histotype (p = 0.0123). No other correlations were found with clinical variables or with EGFR or KRAS mutational status. None of the SNPs had any impact on overall survival or progression-free survival.

Conclusions

The findings suggest that the investigated SNPs do not make any significant contribution to the outcome of NSCLC.

Tumori 2016; 102(4): 367 - 375

Article Type: ORIGINAL RESEARCH ARTICLE

DOI:10.5301/tj.5000526

Authors

Eliana Rulli, Mirko Marabese, Sheila Piva, Lucia Bonomi, Elisa Caiola, Monica Ganzinelli

Article History

Disclosures

Financial support: Supported by grants from the Agenzia Italiana del Farmaco (FARM6F5JER). E.C. was funded by a FIRC fellowship.
Conflict of interest: None of the authors has conflict of interest with this submission.

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

Affiliations

  • Clinical Research Methodology Laboratory, Oncology Department, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan - Italy
  • Molecular Genetics Unit, Oncology Department, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan - Italy
  • Oncology Department, Ospedale Fatebenefratelli e Oftalmico, Milan - Italy
  • Oncology Department, Ospedale Papa Giovanni XXIII, Bergamo - Italy
  • Thoracic Unit, Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan - Italy
  • Elisa Caiola and Monica Ganzinelli contributed equally to this work.

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

This article has supplementary materials available to download.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.